InnoSer

InnoSer is a preclinical contract research organization (CRO) with operations in Belgium and the Netherlands, specializing in rare disease and neurological disorder models.
This section outlines the key features of InnoSer’ preclinical services, representative disease models, and selected nonclinical study examples.

Features of InnoSer’ Contract Services for Non-Clinical Studies

Advanced Mouse Models Across a Broad Range of Disease Areas

InnoSer provides preclinical evaluations using an extensive portfolio of well-characterized and tightly controlled disease models,covering both common and rare disorders.Available models include neurological disease models for genetic disorders such as Fragile X syndrome, 22q11.2 deletion syndrome, and Angelman syndrome, as well as metabolic and cardiovascular disease models.
Comprehensive nonclinical services—combining behavioral assessments, pathological analyses, and PK/PD evaluations—enable detailed characterization of disease-specific effects and pharmacological mechanisms.
All models are precisely designed and maintained to closely reflect human disease pathology with high translational relevance, making them well suited for efficacy and mechanism-of-action studies of drug candidates.

High Standards of Animal Welfare and Quality Control Through AAALAC Accreditation

Preclinical studies are conducted at European animal research facilitiesaccredited by AAALAC International (Association for Assessment and Accreditation of Laboratory Animal Care International),ensuring compliance with globally recognized standards for animal welfare and care. AAALAC accreditation represents an independent validation that animal use is conducted ethically and scientifically, supported by standardized husbandry, health monitoring, and stress-reduction protocols.
In addition, InnoSer holds ISO 9001 certification for quality management systems, ensuring transparency, reproducibility, and regulatory compliance across all research processes.
This robust infrastructure supports the generation of reliable data suitable for regulatory submissions, including IND-enabling study packages.

Integrated Preclinical Study Design and Customized Support

InnoSer’ preclinical services extend beyond model provision to offerintegrated support from early discovery through IND-enabling safety evaluations.Study designs are tailored to each stage of the drug development pipeline, combining pharmacokinetics (PK), toxicology, efficacy studies, pathological evaluation, and biodistribution analyses as required.
The company also supports integrated in vitro and in vivo study designs and offers customized model adaptations and analytical approaches to meet project-specific requirements of pharmaceutical companies and research institutions.
This flexible and integrated framework enables high-precision evaluation of drug efficacy and safety, facilitating efficient progression toward human clinical trials.

Examples of Disease Models Available at InnoSer

The Fmr1 knockout (KO) mouse model developed by InnoSer is a highly translational preclinical model thatrecapitulates key pathological features of human Fragile X syndrome (FXS).
FXS is caused by mutations in the FMR1 gene and is associated with cognitive impairment and autism spectrum disorders. Established on C57BL/6J and FVB genetic backgrounds, this model exhibits altered spontaneous behavior, cognitive deficits, hyperactivity, and reduced social interaction.
Clinically relevant biomarkers, including electrophysiological endpoints such as cortical evoked potentials, can also be assessed, supporting the evaluation of therapeutic candidates.

InnoSer also offers Alzheimer’s disease (AD) models, including multiple transgenic mouse models thatreproduce hallmark AD pathologies such as amyloid plaque formation and tau pathology.These include APP transgenic models, transgenic tau models, and tau seeding models that exhibit abnormal tau accumulation.
The models are designed to assess AD-related phenotypes including neurodegeneration, neuroinflammation, and cognitive and behavioral impairments, and are suitable for evaluating diverse therapeutic approaches such as small molecules, antibody-based therapies, and gene therapies.

InnoSer Non-Clinical Case Study

Efficacy Evaluation Using an Acute Psoriasis-like Skin Inflammation Model

InnoSer has conducted efficacy studies using an IL-23–induced acute skin inflammation model of psoriasis. In this model, intradermal injection of the pro-inflammatory cytokine IL-23 into the mouse ear rapidly induces psoriasis-like features, including increased ear thickness, inflammatory cell infiltration, and epidermal hyperplasia.
The model recapitulates key inflammatory pathways observed in human psoriasis and is well suited for early in vivo evaluation of anti-psoriatic drug candidates. Quantitative assessment of ear swelling and digital pathology analyses demonstrated that the evaluated therapeutic agent exhibited statistically significant efficacy in this IL-23–induced psoriasis model.

InnoSer Company Information